RTW Biotech Opportunities Ltd (LSE: RTWG), a London-listed investment fund focused on biopharmaceutical and medical technology assets, has announced the repurchase of 132,949 ordinary shares at a price of $2.49 per share on 11 November 2026. The repurchased shares will be held in treasury, reducing the total voting rights in the company to 318,464,022. The buyback was conducted under shareholder authority granted at the Annual General Meeting in June 2026, with Jefferies International Limited acting as broker for the transaction.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) is an investment fund managed by RTW Investments, LP, targeting biopharmaceutical and medical technology companies
  • The company repurchased 132,949 ordinary shares at $2.49 per share on 11 November 2026, with shares to be held in treasury
  • Total issued share capital stands at 345,967,440 shares, of which 27,503,418 are now held in treasury and carry no voting rights
  • Investors should monitor the ongoing buyback programme ahead of the next expected shareholder authority at the 2027 AGM

RTW Biotech Repurchases Shares Under June 2026 AGM Authority, Appointing Jefferies as Buyback Broker

The company confirmed that the buyback was executed under authority granted by shareholders at its Annual General Meeting held in June 2026. That authority permits RTW Biotech Opportunities Ltd to repurchase a maximum of 14.99% of its ordinary shares. The arrangement was conducted in accordance with FCA Listing Rules, with Jefferies International Limited instructed as broker for the buyback transactions. The authority remains in force until the next shareholder approval, expected at the Annual General Meeting in 2027, or until expressly revoked by shareholders. The announcement states the actual number of shares repurchased will depend on market conditions.

27,503,418 Ordinary Shares Now Held in Treasury With No Voting Rights

Following settlement of the latest repurchase, RTW Biotech Opportunities Ltd's total issued ordinary share capital stands at 345,967,440 shares. Of these, 27,503,418 are now held in treasury, meaning they attract no voting rights. The resulting total voting rights figure of 318,464,022 serves as the denominator shareholders should use when calculating whether they are required to notify interests or changes in interests under the FCA's Disclosure and Transparency Rules. The company stated it is its current intention to continue holding any repurchased shares in treasury rather than cancelling them.

Buyback Price Capped at Net Asset Value as RTW Investments Manages the Biopharmaceutical Fund

The announcement states that no maximum consideration payable has been determined for the buyback programme; however, the company is prohibited from paying a price for any ordinary shares that would equate to a premium to net asset value. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, described as a healthcare-focused investment firm with scientific expertise and a track record of supporting companies developing life-changing therapies. The fund targets transformative assets across the biopharmaceutical and medical technology sectors, investing in next-generation therapies and technologies. Investors may be watching the pace of buybacks relative to the 14.99% AGM authority cap.